29 results found.

HIV-1 Infection Clinical Trial using Raltegravir

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Non-interventional Cohort Study for the Assessment of the Efficacy of RALTEGRAVIR 400 mg Administered Twice Daily in Combination With Other Antiretroviral Drugs to Treat Infection With the Human Immunodeficiency Virus 1 (HIV-1) in Adults and Aging Patients (ò 50 Years) Under Conditions That Are Representative of the Nationwide Treatment of HIV-positive Patients in Germany.
Raltegravir

Human Immunodeficiency Virus-type 1 Infection Clinical Trial using Rilpivirine; Efavirenz; Tenofovir disoproxil fumarate; Emtricitabine

Janssen-Cilag International NV - Recruiting 18 years or older.
- A Phase 3b, Randomized, Open-label Clinical Study to Demonstrate Non-inferiority in Virologic Response Rates of HIV-1 RNA Suppression <400 Copies/mL of TDF/FTC/RPV Versus TDF/FTC/EFV in First-line Antiretroviral NNRTI-based Suppressed Patients. Switching At Low HIV-1 RNA Into Fixed Dose Combinations (SALIF).
Rilpivirine; Efavirenz; Tenofovir disoproxil fumarate; Emtricitabine

HIV Infection, or Unspecified Adult Solid Tumor, Protocol Specifi Clinical Trial using cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection.
cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

Human Immunodeficiency Virus (HIV) Clinical Trial using Maraviroc

ViiV Healthcare - Recruiting 2 years to 18 years.
- An Open-Label, Multicenter, Multiple-Dose Pharmacokinetic, Safety And Efficacy Trial Of Maraviroc In Combination With Optimized Background Therapy For The Treatment Of Antiretroviral-Experienced CCR5-Tropic HIV-1 Infected Children 2 - <18 Years Of Age.
Maraviroc

Human Immunodeficiency Virus Clinical Trial using Maraviroc along with an optimized background antiretroviral drug regimen; Optimized background antiretroviral drug regimen without maraviroc

ViiV Healthcare - Recruiting 18 years or older.
- An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-Experienced HIV-1 Infected Patients.
Maraviroc along with an optimized background antiretroviral drug regimen; Optimized background antiretroviral drug regimen without maraviroc

HIV Clinical Trial using antiretroviral therapy; cell phone reminders; contingency management for adherence

University of Connecticut Health Center - Recruiting 18 years or older.
- Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus.
antiretroviral therapy; cell phone reminders; contingency management for adherence

Hepatitis C, or Human Immunodeficiency Virus Clinical Trial using Boceprevir

Erasmus Medical Center - Recruiting 18 years or older.
- Efficacy of 12 Week Boceprevir in Addition to Standard of Care Therapy Consisting of Peginterferon-alpha-2b and Ribavirin for the Treatment of Acute HCV Genotype 1 in HIV Co-infected Patients. A Proof of Concept Feasibility Clinical Trial..
Boceprevir

Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficie Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 14 years or older.
- Characterization and Management of Patients With HIV-1 Infection Who Experience Virologic Failure Despite Combination Antiretroviral Therapy.

HIV Infections Clinical Trial using MK-1439; Efavirenz; TRUVADAr

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients.
MK-1439; Efavirenz; TRUVADAr

Hepatitis C, Chronic, or Human Immunodeficiency Virus Clinical Trial using DAA against HCV

Valme University Hospital - Recruiting 18 years or older.
- Security and Efficacy of Triple Therapy Including Direct-Acting Antivirals Against Chronic Hepatitis C Infection In HIV-Coinfected Patients In Real-Life Conditions: The Prospective HEPAVIR Cohort..
DAA against HCV

Inflammation, Macrophage Infiltration, or Cardiovascular Disease Clinical Trial using Sitagliptin; Placebo

Washington University School of Medicine - Recruiting 18 years to 65 years.
- A Double Blind, Randomized, Placebo Controlled Study to Determine the Physiological Effectiveness of Januvia (100 mg/d) for Reducing Inflammation and Increasing Endothelial Progenitor Cell Number in Human Immunodeficiency Virus (HIV) Infected Men and Women With Insulin Resistance and Central Adiposity..
Sitagliptin; Placebo

Human Immunodeficiency Virus (HIV), or Acquired Immune Deficiency Clinical Trial

Columbia University - Recruiting 1 Month to 12 years.
- Enhanced Surveillance and 2 Year Outcomes of Children Enrolled on Antiretroviral Therapy (ART) in Public Health Facilities in the Eastern Cape Province, South Africa.

HIV-1 Infection Clinical Trial

Gen-Probe, Incorporated - Recruiting 15 years or older.
- Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay.

Human Immunodeficiency Virus (HIV) Clinical Trial using Sexual Health Counseling; Enhanced Adherence Intervention; PrEP Information (Active Control); Standard of Care Adherence Support (Active Control)

Hunter College - Recruiting 18 years or older.
- Intervention to Enhance PrEP Uptake and Adherence in a Community-Based Setting.
Sexual Health Counseling; Enhanced Adherence Intervention; PrEP Information (Active Control); Standard of Care Adherence Support (Active Control)

Human Immunodeficiency Virus, or Neurocognitive Impairment Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 25 years to 55 years.
- Neurovascular Magnetic Resonance Imaging in the Assessment of HIV-Associated Neurocognitive Disorders.

Human Immunodeficiency Virus (HIV) Clinical Trial using Enhanced Treatment Support (ETS)

Karolinska Institutet - Recruiting N/A to 12 years.
- A Randomized Controlled Trial to Assess the Effect of Group Peer Support to Children With HIV in Relation to Adherence, Virological Treatment Failure as Well as Physical Development.
Enhanced Treatment Support (ETS)

HIV Infections Clinical Trial

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years to 64 years.
- Observational Study Assessing the Safety, Efficacy and Treatment Adherence of Nevirapine Extended Release (Combined With Other Antiretroviral Drugs) in HIV Infected Patients in Daily Clinical Practice.

Human Immunodeficiency Virus (HIV), or Hepatitis C, Chronic Clinical Trial

George Washington University - Recruiting 18 years or older.
- The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System..

Human Immunodeficiency Virus (HIV), or Acquired Immune Deficiency Clinical Trial using HIV Self-testing with Standard Counseling and Testing (SCT) Confirmation

Columbia University - Recruiting 18 years or older.
- Enhanced HIV Prevention in Serodiscordant Couples Study #3: Feasibility of Home-based Partner Self Testing for HIV.
HIV Self-testing with Standard Counseling and Testing (SCT) Confirmation

Infection, Human Immunodeficiency Virus Clinical Trial using Dolutegravir/abacavir/lamivudine FDC; Atazanavir; Ritonavir; Tenofovir/emtricitabine FDC

ViiV Healthcare - Recruiting 18 years or older.
- A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Na‹ve Women.
Dolutegravir/abacavir/lamivudine FDC; Atazanavir; Ritonavir; Tenofovir/emtricitabine FDC

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using leukapheresis; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; laboratory biomarker analysis; DNA analysis; RNA analysis; flow cytometry; reverse transcriptase-polymerase chain reaction; nucleic acid sequencing; protein expression analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A to 75 years.
- Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected With HIV.
leukapheresis; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; laboratory biomarker analysis; DNA analysis; RNA analysis; flow cytometry; reverse transcriptase-polymerase chain reaction; nucleic acid sequencing; protein expression analysis

HIV, or Human Immunodeficiency Virus Clinical Trial using Disulfiram

University of California, San Francisco - Recruiting 18 years or older.
- Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study.
Disulfiram

Human Immunodeficiency Virus Clinical Trial using Raltegravir; Fluconazole; Azithromycin; Albendazole; Isoniazid; Ready to Use Supplementary Food

Medical Research Council - Recruiting 5 years or older.
- Reduction of Early mortALITY in HIV-infected African Adults and Children Starting Antiretroviral Therapy: a Randomised Controlled Trial.
Raltegravir; Fluconazole; Azithromycin; Albendazole; Isoniazid; Ready to Use Supplementary Food

Chronic HIV Infection, or HCV Coinfection Clinical Trial using Fosamprenavir

Fundacion SEIMC-GESIDA - Recruiting 18 years or older.
- Randomized, Controlled, Open Label, Pilot Study to Evaluate Fosamprenavir Activity on Genotype 1 Hepatitis C Virus (HCV) Infection Evolution in Human Immunodeficiency Virus (HIV) Co-infected Subjects With Antiretroviral Treatment Including Fosamprenavir.
Fosamprenavir

Human Immunodeficiency Virus Clinical Trial using TwHF; placebo treatment

Beijing 302 Hospital - Recruiting 18 years to 60 years.
- Phase 1/2 Study of Tripterygium Wilfordii Hook F (TwHF) Treatment for Evaluation the Efficacy and Safety in Immune Non-responders With HIV-1 Infection.
TwHF; placebo treatment

HIV Infection Clinical Trial

Bristol-Myers Squibb - Recruiting N/A to 17 years.
- Post-marketing Safety Surveillance Program in HIV-infected Children Exposed to Atazanavir in Europe.

HIV Disease Clinical Trial using à1 Proteinase Inhibitor; Placebo

AIDS Community Research Initiative of America - Recruiting 18 years to 65 years.
- A Double Blind, Randomized Trial to Evaluate the Safety and Efficacy of 8 Weekly Doses of Prolastinr-C (à1Proteinase Inhibitor, à1PI) in Human Immunodeficiency Virus-Infected Subjects Who Are 18 to 65 Years of Age and Who Are on Antiretroviral Therapy.
à1 Proteinase Inhibitor; Placebo

HIV, AIDS, Opioid Dependence, or Drug Dependence Clinical Trial using Depot Naltrexone

Yale University - Recruiting 18 years or older.
- Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations.
Depot Naltrexone

HIV Infections Clinical Trial using Pioglitazone; Observation

University of Texas Southwestern Medical Center - Recruiting 18 years or older.
- Human Immunodeficiency Virus Acquired Lipodystrophy (HAL) Classification, Measurement, & Fat Response to a Thiazolidinedione (TZD) Challenge in Differing Adult Phenotypic Presentations.
Pioglitazone; Observation